Tolfenamic Acid

證據等級: L5

預測適應症: 10 個

Tolfenamic Acid: From Anti-Inflammatory Analgesic to Headache Disorder

One-Sentence Summary

Tolfenamic acid is a fenamate-class NSAID with a long clinical history as an anti-inflammatory analgesic (detailed original-indication data is not present in this evidence pack). The TxGNN model predicts it may be effective for Headache Disorder (migraine), with 0 registered clinical trials but 20 supporting publications — including at least 9 randomized controlled trials conducted between 1979 and 2002.

Quick Overview

Item	Content
Original Indication	Not specified in evidence pack (drug not currently marketed; historically classified as an anthranilic acid/fenamate NSAID used for pain, inflammation and rheumatic disease)
Predicted New Indication	Headache disorder
TxGNN Prediction Score	99.74%
Evidence Level	L1
Germany Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, no structured mechanism-of-action (MOA) record is available for tolfenamic acid in this evidence pack (Data Gap DG002). However, the supporting literature is informative: multiple publications describe tolfenamic acid as a fenamate-class NSAID that is "a potent inhibitor of prostaglandin biosynthesis" (PMID 6984358) and, unusually among NSAIDs, also suppresses leukotriene synthesis, which may reduce upper-GI side effects relative to pure COX inhibitors (PMID 7816786).

Because no original-indication text is on file, the exact starting point for this repurposing candidate cannot be stated precisely. What the literature does show is that tolfenamic acid already has an extensive, decades-long track record as an anti-inflammatory analgesic (rheumatic disease, general pain) — so its application to headache disorder is less a "novel leap" and more a well-documented, longstanding clinical use pattern that the TxGNN model has independently recovered from the underlying knowledge graph.

Mechanistically, prostaglandins are implicated in migraine pathophysiology — sensitizing nociceptors, promoting vasodilation, and modulating platelet-serotonin release (PMID 7816790). COX inhibition by tolfenamic acid directly addresses this pathway, which is consistent with the drug's high TxGNN prediction score and with the large body of comparative RCT evidence (vs. ergotamine, sumatriptan, propranolol, paracetamol, and pizotifen) summarized below.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
89390	1979	RCT (double-blind crossover)	Lancet	Tolfenamic acid as effective as ergotamine in acute migraine, with fewer side effects (less nausea)
6984358	1982	RCT (double-blind, randomized order)	Cephalalgia	Tolfenamic acid + caffeine/metoclopramide/pyridoxine combinations tested across 60 acute migraine attacks
7051739	1982	RCT (double-blind crossover vs placebo)	Acta Neurol Scand	Significant prophylactic benefit vs placebo: fewer attacks, shorter duration, less vomiting
6394143	1984	RCT (controlled)	Cephalalgia	Compared tolfenamic acid, caffeine, metoclopramide and combinations for acute migraine
3727918	1986	RCT (double-blind crossover vs propranolol/placebo)	Acta Neurol Scand	Both tolfenamic acid and propranolol significantly reduced attack frequency and duration vs placebo
2375249	1990	RCT (double-blind crossover vs paracetamol)	Acta Neurol Scand	Dose-ranging comparison (200/400 mg vs paracetamol 500/1000 mg) in common migraine
7976233	1994	RCT (randomized double-blind crossover vs propranolol)	Acta Neurol Scand	76-patient trial; both drugs significantly effective in migraine prophylaxis
9563211	1998	RCT (double-blind, randomized, parallel-group vs sumatriptan)	Headache	Comparable efficacy to oral sumatriptan in acute migraine (77% response rate)
12474702	2002	RCT (prospective, randomized, double-blind, parallel-group vs pizotifen)	Medicina (Kaunas)	192-patient migraine prophylaxis trial comparing tolfenamic acid 300 mg vs pizotifen
7816790	1994	Review	Pharmacology & Toxicology	Reviews prostaglandin-mediated mechanism underlying tolfenamic acid's antimigraine effect

Germany Market Information

Tolfenamic acid is currently not marketed in Germany, and no BfArM authorization records are present in this evidence pack (0 licenses on file).

Safety Considerations

Please refer to the package insert for safety information.

(Key warnings, contraindications, and DDI data are flagged as data gaps in this evidence pack — DG001, "TFDA/BfArM label warnings/contraindications," is marked as a Blocking severity gap.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Although no clinical trials are currently registered for headache disorder, the literature base is unusually strong for an older drug — at least 9 randomized controlled trials (1979–2002) consistently demonstrate efficacy in acute and prophylactic migraine, including head-to-head comparisons against ergotamine, sumatriptan, propranolol, and pizotifen. This meets L1 evidence criteria, but the drug's current unmarketed status in Germany and missing safety-label data mean guardrails are required before any regulatory or clinical action.

To proceed, the following is needed:

Package insert / BfArM label data on warnings and contraindications (Blocking gap, DG001)
Structured DrugBank MOA record (High priority gap, DG002)
Confirmation of why the drug is currently unmarketed in Germany, and what registration pathway would be required to reintroduce it for a headache indication
Updated drug-drug interaction (DDI) data, as none is currently on file
A contemporary systematic review of the 1979–2002 RCT literature to formally grade study quality (risk of bias, sample sizes) before treating this as decision-grade evidence
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.